CDKL3 is a Targetable Regulator of Cell Cycle Progression in Cancers
Haijiao Zhang,Jiahui Lin,Shaoqin Zheng,Lanjing Ma,Zhongqiu Pang,Hongyi Yin,Chengcheng Meng,Yinuo Wang,Qing Han,Xi Zhang,Zexu Li,Liu Cao,Lijun Liu,Teng Fei,Daming Gao,Liang Yang,Xueqiang Peng,Chen Ding,Shixue Wang,Ren Sheng
DOI: https://doi.org/10.1172/jci178428
IF: 19.456
2024-01-01
Journal of Clinical Investigation
Abstract:Cell cycle regulation is largely abnormal in cancers. Molecular understanding and therapeutic targeting of the aberrant cell cycle are essential. Here, we identified that an underappreciated serine/threonine kinase, cyclin-dependent kinase-like 3 (CDKL3), crucially drives rapid cell cycle progression and cell growth in cancers. With regard to mechanism, CDKL3 localizes in the nucleus and associates with specific cyclin to directly phosphorylate retinoblastoma (Rb) for quiescence exit. In parallel, CDKL3 prevents the ubiquitin-proteasomal degradation of cyclin-dependent kinase 4 (CDK4) by direct phosphorylation on T172 to sustain G1 1 phase advancement. The crucial function of CDKL3 in cancers was demonstrated both in vitro and in vivo. We also designed, synthesized, and characterized a first-in-class CDKL3-specific inhibitor, HZ1. HZ1 exhibits greater potency than CDK4/6 inhibitor in pan-cancer treatment by causing cell cycle arrest and overcomes acquired resistance to CDK4/6 inhibitor. In particular, CDKL3 has significant clinical relevance in colon cancer, and the effectiveness of HZ1 was demonstrated by murine and patient-derived cancer models. Collectively, this work presents an integrated paradigm of cancer cell cycle regulation and suggests CDKL3 targeting as a feasible approach in cancer treatment.